Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gc Cell Corp. (144510:KRX), powered by AI.
Gc Cell Corp. is currently trading at ₩17,320. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Gc Cell Corp. on Alpha Lenz.
Gc Cell Corp.'s P/E ratio is -1.0.
“Gc Cell Corp. trades at a P/E of -1.0 (undervalued) with modest ROE of -84.7%.”
Ask for details →Gc Cell Corp. is primarily a biotechnology company focused on the research, development, and commercialization of cell therapies. The company plays a pivotal role in advancing medicinal biotechnology, particularly through its innovative approaches to harnessing the therapeutic potential of cellular and genetic sciences. Gc Cell Corp.'s work is largely concentrated in creating cutting-edge treatments aimed at addressing a wide range of diseases, including those that are currently considered challenging to treat with conventional methods. By leveraging advancements in biotechnological processes, the company seeks to provide transformational therapies that can improve patient outcomes and healthcare solutions globally. Its impact is notably seen in sectors such as personalized medicine, cancer treatment, and regenerative medicine, where breakthroughs in cell-based technologies have the potential to revolutionize standard care practices. Gc Cell Corp.'s position in the market underscores its importance in the ongoing development of advanced therapeutic solutions, contributing to both industry innovation and increased accessibility to life-saving treatments.
“Gc Cell Corp. trades at a P/E of -1.0 (undervalued) with modest ROE of -84.7%.”
Ask for details →Gc Cell Corp. (ticker: 144510) is a company listed on KRX in the Healthcare sector (Diagnostics & Research). It has approximately 752 employees. Market cap is $273.7B.
The current price is ₩17,320 with a P/E ratio of -1x and P/B of 1.47x.
ROE is -84.71% and operating margin is -8.33%. Annual revenue is $165.5B.